Unmet Need and Treatment Disparities Among Lupus Patients with Medicaid Insurance in the United States (ACR Convergence 2026) - Sep 8, 2026 - Abstract #286; Pres time: Nov 8, 2026; 10:30 AM - 12:30 PM; Location: WB1&2; In Person; "Patients were stratified by disease states of LN or extra-renal SLE and race/ethnicity and the following treatment endpoints were assessed within these strata: (1) Receipt of any nonsteroidal immunosuppression; (2) receipt of any aTX (belimumab, anifrolumab for SLE and belimumab, voclosporin for LN); and (3) receipt of hydroxychloroquine, the foundational therapy for treatment of lupus. In this study of Medicaid-insured individuals with SLE or LN, most patients were undertreated. While significant differences in receipt of treatment according to race/ethnicity were not observed in this study, it is concerning that many patients received neither hydroxychloroquine nor nonsteroidal immunosuppression therapy and that large majorities of patients did not receive aTX."
Clinical • Medicaid • Reimbursement • US reimbursement • Glomerulonephritis • Human Immunodeficiency Virus • Immunology • Infectious Disease • Inflammatory Arthritis • Lupus • Lupus Nephritis • Nephrology • Renal Cell Carcinoma • Renal Disease • Respiratory Diseases • Systemic Lupus Erythematosus • Tuberculosis
|
|
Jesse Sussell1; Zhiyu Xia2; Roongrong Wang1; William Pendergraft III1; Maria Dall'Era3
|